Study on the Effectiveness and Safety of Gamunex for Patients with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Inclusion Criteria

• Have a confirmed diagnosis of one of the following:
  • B-cell Chronic Lymphocytic Leukemia (CLL) at intermediate or high stages.
  • Multiple Myeloma (MM) at stage II or III.
  • B-cell Non-Hodgkin Lymphoma (NHL) at stage III or higher.
• Have low levels of a specific antibody (IgG) in the blood.

Exclusion Criteria

• Have had a stem cell transplant in the last 6 months.
• Currently receiving or have recently received immunoglobulin replacement therapy.
• Have active infections or other cancers at the time of screening.
• Have a known primary immune deficiency.
• Have a life expectancy of less than 1.5 years.
• Have significant health issues that could interfere with the study.
• Have had serious reactions to immunoglobulin or blood products.
• Have a specific type of antibody deficiency (Selective IgA Deficiency).
• Women who are pregnant, breastfeeding, or not using effective birth control.
• Have severe kidney disease or high liver enzyme levels.
• Have a history of blood clots or certain heart conditions.
• Have conditions that affect blood thickness or clotting.
• Have active hepatitis B or C infections.
• Have uncontrolled high blood pressure or a high heart rate.
• Have a history of substance abuse.
• Have participated in another clinical trial recently.
• Are unable or unwilling to follow the study procedures.